Table 3. BMD, daily GC dose (GD/day) and cumulative GC dose (cGCD) in patients with and without pretreatment with bDMARDS with disease duration >2 years ((A) all patients; (B) patients without bisphosphonates).
| BMD-LS (g/cm2) | BMD-SH (g/cm2) | BMD-H (g/cm2) | GD/day (mg) | cGCD (g) | |
| (A)Allpatients | |||||
| No pretreatment with bDMARDS(n=578) | 0.89±0.18 | 0.72±0.15 | 0.84±0.17 | 5.2±6.7 | 18.7±25.9 |
| Pretreatment with bDMARDS(n=122) | 1.00±0.21 | 0.80±0.13 | 0.90±0.14 | 5.4±3.5 | 26.8±21.0 |
| P value | <0.001 | <0.001 | <0.001 | ns. | <0.001 |
| (B)Patientswithout bisphosphonates | |||||
| No pretreatment with bDMARDS(n=487) | 0.90±0.19 | 0.74±0.15 | 0.85±0.17 | 5.3±7.2 | 17.1±26.0 |
| Pretreatment with bDMARDS(n=91) | 1.03±0.22 | 0.82±0.13 | 0.92±0.14 | 5.3±3.4 | 25.5±22.9 |
| P value | <0.001 | <0.001 | <0.001 | ns. | <0.001 |
bDMARDs, biologic disease-modifying antirheumatic drugs; BMD, bone mineral density; BMD-FN, BMD femoral neck; BMD-H, BMD total hip; BMD-LS, BMS lumbar spine; cGCD, cumulative glucocorticoid dose; GD/day, glucocorticoid dose per day; ns, not significant